Heparin reexposure in patients with a history of heparin-induced thrombocytopenia

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 7, 2015, Pages 626-631

  Dhakal, Prajwal ^a   Giri, Smith ^b   Pathak, Ranjan ^c   Bhatt, Vijaya Raj ^d  

^a TRIBHUVAN UNIVERSITY   (Nepal)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Reading Health System   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

heparin induced thrombocytopenia; low molecular weight heparin; nonheparin anticoagulant; plasma exchange; reexposure; unfractionated heparin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALTEPLASE; APROTININ; ARGATROBAN; CLOPIDOGREL; DRUG ANTIBODY; ENOXAPARIN; FIBRIN GLUE; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; NADROPARIN; PHENPROCOUMON; TIROFIBAN; ANTICOAGULANT AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; AORTA VALVE REPLACEMENT; BLEEDING; CONFERENCE PAPER; DRUG REEXPOSURE; DRUG SAFETY; FEMALE; HEART SURGERY; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT SAFETY; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM; TREATMENT INDICATION; VASCULAR SURGERY; BLOOD; CARDIOPULMONARY BYPASS; CHEMICALLY INDUCED; DRUG MONITORING; THROMBOCYTOPENIA;

ANTICOAGULANTS; CARDIOPULMONARY BYPASS; DRUG MONITORING; FEMALE; HEPARIN; HUMANS; MALE; THROMBOCYTOPENIA;

EID: 84940833557     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029615578167     Document Type: Conference Paper

References (42)

1. Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G,. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010; 110 (1): 30-35.
2. Cuker A, Cines DB,. How I treat heparin-induced thrombocytopenia. Blood. 2012; 119 (10): 2209-2218.
3. Koster A, Dyke CM, Aldea G,. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007; 83 (2): 572-577.
4. Martin ME, Kloecker GH, Laber DA,. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol. 2007; 78 (2): 161-166.
5. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F,. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2002; 57 (2): 177-184.
6. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A,. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4 (4): 759-765.
7. Ganjoo AK, Harloff MG, Johnson WD,. Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg. 1996; 112 (5): 1390-1392.
8. Jaben EA, Torloni AS, Pruthi RK, Winters JL,. Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature. J Clin Apher. 2011; 26 (4): 219-224.
9. Kajitani M, Aguinaga M, Johnson CE, Scott MA, Antakli T,. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. J Cardiac Surg. 2001; 16 (4): 313-318.
10. Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A,. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clinical Appl Thromb Hemost. 2007; 13 (2): 182-187.
11. Matsuo T, Matuo M, Wanaka K, Sakai R,. Heparin re-exposure after heparin-induced thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haematol. 2003; 25 (5): 333-334.
12. Maurin N, Biniek R, Heintz B, Kierdorf H,. Heparin-induced thrombocytopenia and thrombosis with spinal ischaemia - recovery of platelet count following a change to a low molecular weight heparin. Intensive Care Med. 1991; 17 (3): 185-186.
13. Neuray M, Balling G, Schreiber C, Martin K,. Two consecutive open heart operations in a small child with heparin-induced thrombocytopenia type II using anticoagulation with heparin and tirofiban. Ann Thorac Surg. 2012; 94 (2): 653-655.
14. Patrassi GM, Luzzatto G,. Heparin-induced thrombocytopenia with thrombosis of the aorta, iliac arteries and right axillary vein successfully treated by low-molecular weight heparin. Acta Haematologica. 1994; 91 (1): 55-56.
15. Voeller RK, Melby SJ, Grizzell BE, Moazami N,. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2010; 140 (3): e56-e58.
16. Warkentin TE, Sheppard JA,. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood. 2014; 123 (16): 2485-2493.
17. Gottlieb A, Tabares AH, Levy P, Sprung J, Kottke-Marchant K, Schoenwald PK,. Use of low molecular weight heparin in patients with heparin-induced thrombocytopenia undergoing carotid endarterectomy. Anesthesiology. 1996; 85 (3): 678-681.
18. Gruel Y, Lang M, Darnige L,. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet. 1990; 336 (8722): 1077-1078.
19. Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P,. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract. 2006; 104 (4): c143-c148.
20. Koster A, Kukucka M, Bach F,. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology. 2001; 94 (2): 245-251.
21. Koster A, Loebe M, Mertzlufft F, Kuppe H, Hetzer R,. Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann Thorac Surg. 2000; 70 (6): 2160-2161.
22. Koster A, Meyer O, Fischer T,. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg. 2001; 122 (6): 1254-1255.
23. Kramer R, Oberg-Higgins P, Russo L, Braxton JH,. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis. Interact Cardiovasc Thorac Surg. 2009; 8 (4): 439-441.
24. Potzsch B, Klovekorn WP, Madlener K,. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000; 343 (7): 515.
25. Robitaille D, Leclerc JR, Laberge R, Sahab P, Atkinson S, Cartier R,. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg. 1992; 103 (3): 597-599.
26. Schreiber C, Dietrich W, Braun S, Kostolny M, Eicken A, Lange R,. Use of heparin upon reoperation in a pediatric patient with heparin-induced thrombocytopenia after disappearance of antibodies. Clin Res Cardiol. 2006; 95 (7): 379-382.
27. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A,. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008; 112 (10): 4024-4027.
28. Selleng S, Lubenow N, Wollert HG, Mullejans B, Greinacher A,. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin. Ann Thorac Surg. 2001; 71 (3): 1041-1042.
29. von Heymann C, Hagemeyer E, Kastrup M,. Heparin-induced thrombocytopenia type II in an infant with a congenital heart defect - anticoagulation during cardiopulmonary bypass with epoprostenol sodium and heparin. Pediatr Crit Care Med. 2006; 7 (4): 383-385.
30. Wadia Y, Cooper JR, Bracey AW, Pinto K, Frazier OH,. Intraoperative anticoagulation management during cardiac transplantation for a patient with heparin-induced thrombocytopenia and a left ventricular assist device. Texas Heart Inst J. 2008; 35 (1): 62-65.
31. Wanaka K, Matsuo T, Matsuo M,. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost. 2010; 8 (3): 616-618.
32. Warkentin TE, Kelton JG,. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001; 344 (17): 1286-1292.
33. Newcombe RG,. Two-Sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17 (8): 857-872.
34. Warkentin TE, Bernstein RA,. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med. 2003; 348 (11): 1067-1069.
35. Winters JL,. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. ASH Education Program Book. 2012; 2012 (1): 7-12.
36. Abdel-Razeq HN, Bajouda AA, Khalil MM, Ashmeg AK,. Treating heparin-induced thrombocytopenia. The unconventional way! Saudi Med J. 2004; 25 (9): 1258-1260.
37. Brady J, Riccio J, Yumen O, Makary A, Greenwood S,. Plasmapheresis. A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol. 1991; 96 (3): 394-397.
38. Poullin P, Pietri PA, LefÈvre P,. Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange. Br J Haematol. 1998; 102 (2): 629-630.
39. Nand S, Robinson JA,. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol. 1988; 28 (3): 204-206.
40. Robinson JA, Lewis BE,. Plasmapheresis in the management of heparin-induced thrombocytopenia. Semin Hematol. 1999; 36 (1 suppl 1): 29-32.
41. Schwartz J, Winters JL, Padmanabhan A,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013; 28 (3): 145-284.
42. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A,. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood. 2015; 125 (1): 195-198.